VS 4718

Drug Profile

VS 4718

Alternative Names: VS-4718

Latest Information Update: 09 Feb 2017

Price : $50

At a glance

  • Originator The Scripps Research Institute
  • Developer Verastem
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Focal adhesion protein-tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pancreatic cancer; Solid tumours
  • Preclinical Acute myeloid leukaemia

Most Recent Events

  • 26 Jan 2017 Verastem terminates a phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Combination therapy) and Pancreatic cancer (Late-stage disease, Inoperable/Unresectable, Combination therapy, First-line therapy) in USA due to Verastem's decision to de-prioritise VS 4718 development (PO) (NCT02651727)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in USA (PO)
  • 16 Mar 2016 Pharmacodynamics data from a preclinical studies in Squamous cell carcinoma and Ovarian cancer released by Verastem
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top